Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

8 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    a Immunofluorescence of HA–cGAS in transfected HCA2-TERT cells exposed to etoposide (100 μg/ml) for 4 h. b, Immunoblot of endogenous cGAS in the cytoplasmic and nuclear fractions of HCA2-TERT cells treated with etoposide for the indicated times

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

  • j, Immunoblot of cell lysates of PC-9 cells that stably express HA–cGAS, transfected with either shCtrl or shBLK after etoposide (100 μg ml−1) treatment for 4 h.

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NV3VNWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7kdlVKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN NWHUZ5hDOjV7NkCyPFI>
KellyCis83 M{DtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XURWlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= NEPsPJgzPTl4MEK4Ni=>
SK-N-AS NVHz[|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XRUWlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NWPLPYdkOjV7NkCyPFI>
SK-N-ASCis24 M133S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NEHpfXUzPTl4MEK4Ni=>
U87 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIflAuPTBizszN MWS0PEBp NILjTI9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= NGjkXVEzPTd3MEK3Ny=>
HCT116 NHv5b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvUNE42NTJwNTFOwG0> NH3p[JY1QMLiaNMg Mkj1TWM2OD1zLkezxsDDucLiMD6yNeKh|ryP M{HUV|I2PzR4N{[z
HT-29 NE\3fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHL[JlvOC53LUKuOUDPxE1? M4XXe|Q5yqCqwrC= M2DZWWlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NFP0cHUzPTd2Nke2Ny=>
Caco2 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnuRpYxNjVvMj61JO69VQ>? MWi0POKhcMLi M3XYUmlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= NELveGszPTd2Nke2Ny=>
COLO 205 M3XwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nTUlAvPS1{LkWg{txO NIHKSWE1QMLiaNMg NV7NVZNlUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN MV[yOVc1Pjd4Mx?=
SW480 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6wMlUuOi53IN88US=> M4DxRVQ5yqCqwrC= MWHJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? MYWyOVc1Pjd4Mx?=
HEK293T NU\BcI9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fLXVEuPSEQvF2= NV7C[WVRPDkEoHlCpC=> MVLJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? MVyyOVc1Pjd4Mx?=
Hep3B  M3rlcmZ2dmO2aX;uJGF{e2G7 MWSxNEDPxE1? M3u3OlQ5yqCqwrC= M3;HWJJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> MlvzNlU3OzN3NkS=
Hep3B  NYLWdphYTnWwY4Tpc44hSXO|YYm= NFjHb4oxNjFvMUCg{txO MlfGNlQhcA>? MYjzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NIK0SXUzPTZ|M{W2OC=>
HEK293 NXjneHFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe2cWlRUUN3ME23MlE1yqEEsdMgNE4{PsLizszN M2WzXVI2PjB|MUKy
DU145 NVXKTIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O1TmlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= MV2yOVYxOzF{Mh?=
HCT15 NVW2ZmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TYTGlEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= MYSyOVYxOzF{Mh?=
T47D M1TDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrmZlhyUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN M3XSVlI2PjB|MUKy
SMMC-7721 NEDKcJdHfW6ldHnvckBCe3OjeR?= NIrqV5U1OCEQvF2= M{\JSlQ5KGh? MUDEUXNQ NUfRR4NbcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? MmjJNlU2PDR|NkG=
MDA-MB-231 NVS1Z2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfvN3Q4OsLiaB?= M2L2NWlEPTB;MkGuNuKhyrIEoESuNuKh|ryP Mo\JNlU1QDZ{MUm=
MCF-7 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\3O|LDqGh? NGXBWJlKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= MVyyOVQ5PjJzOR?=
Jurkat NFjDfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NuKhcA>? NF;lPFRKSzVyPUGuNuKhyrIEoEGuOeKh|ryP M2nGclI2PDh4MkG5
HeLa MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC3NuKhcA>? NX7jRVRSUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= M2jZUlI2PDh4MkG5
MCF7  M3;J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknYOU0yODBizszN NYrKXXFIPyCm MknmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYDwfItFOjV2N{K2NVk>
K562 M3:5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f1VlczyqCq NWrWW2pbUUN3ME2wMlI6yqEQvF2= M3;kS|I2Ojh{NkWz
K/VP.5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\BO|LDqGh? NX24TJdnUUN3ME20MlnDqM7:TR?= NFLXfnYzPTJ6Mk[1Ny=>
SH-EP  M4rkTWZ2dmO2aX;uJGF{e2G7 MX6yNOKh|rypL33s NF7NfZMzPMLiaB?= NUnzRWJJcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> M2ixeFI2OjZzOUix
SCC25 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfId4R6OjUEoHi= M1f0bGlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= M3PFdVI2OjJyN{K5
CAL27 MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGyOOKhcA>? M2KzXmlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= M4K4XVI2OjJyN{K5
FaDu MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT1NlTDqGh? MoX1TWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= MX6yOVIzODd{OR?=
SCC25 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvzWo01QMLiaB?= NWXHXWNmUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> MUeyOVIzODd{OR?=
CAL27 NVi3S|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[0POKhcA>? MVTJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP NFL0Wo0zPTJ{MEeyPS=>
FaDu MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW0POKhcA>? NGjyUWhKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= Mk\XNlUzOjB5Mkm=
SCC25 NEXsdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[3NuKhcA>? NHf0Z5VKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= MlT0NlUzOjB5Mkm=
CAL27 M4\jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjpXWhqPzMEoHi= M3TSOGlEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NXjnW5dJOjV{MkC3Nlk>
FaDu MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NuKhcA>? M332NWlEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= MViyOVIzODd{OR?=
MCF-7 NHy1SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCZ2pFPDkEoHlCpC=> NGjwcm1FVVOR M2f4dGlEPTB;Nz6yxsDDucLiMD64xsDPxE1? MlTUNlUzOTZ|N{i=
T-47D M1nJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq0OFjDqGkEoB?= NVHkeYdvTE2VTx?= M3jPeWlEPTB;Nz63xsDDucLiMD63xsDPxE1? M2XUNlI2OjF4M{e4
MDA-MB-231 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfMdYdEPDkEoHlCpC=> MoLxSG1UVw>? M3\PUGlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP M4HVUFI2OjF4M{e4
DU145 MnPMRZBweHSxc3nzJGF{e2G7 MYixNE0yODBizszN MWW4JIg> MYjEUXNQ Mne1bY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w Mkf4NlUyPDl4OEG=
DU145 stem-like MoH4RZBweHSxc3nzJGF{e2G7 MVWxNE0yODBizszN Mn;qPEBp M2rDOWROW09? NGfjXYVqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnLBNlUyPDl4OEG=
DU145 NGT2OVNHfW6ldHnvckBCe3OjeR?= NULGOnFYOTBvMUCwJO69VQ>? M1HQXlIhcA>? MmToSG1UVw>? M4nTNYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHvOZ24zPTF2OU[4NS=>
DU145 stem-like M{XVOWZ2dmO2aX;uJGF{e2G7 NUfwSI0xOTBvMUCwJO69VQ>? NE\DWHYzKGh? NVLpVFBpTE2VTx?= NYjhbWJOcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIjVNVIzPTF2OU[4NS=>
UW228-3 NU[xWpdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlAyNTNyMDFOwG0> MYW0PEBp NFO3VnNFVVOR NX\zSWFRUUN3ME2wMlk6yqEQvF2= MVWyOVEyQTF6NR?=
NSCs MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMlAyNTNyMDFOwG0> NW\0WmttPDhiaB?= M37IR2ROW09? MmLiTWM2OD1yLkOtN:Kh|ryP MomwNlUyOTlzOEW=
MKL-1  M17uNWZ2dmO2aX;uJGF{e2G7 NWn4NFdoOTBvMUCwNEBvVQ>? NFHRR3g1KGR? NVr6TpM1cW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MXWyOVEyPjd3NB?=
MCF7 EV NVfXWWtpTnWwY4Tpc44hSXO|YYm= NWfKU5BiOTBvMUCwJO69VQ>? NXPPb4M{OuLCiXi= M{jwR4lv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ M1zR[lI2ODh6MkCz
MCF 7BMI1 M4XvW2Z2dmO2aX;uJGF{e2G7 NULSS3VSOTBvMUCwJO69VQ>? MV2y5qCKcA>? NFjHNVZqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? MkX2NlUxQDh{MEO=
MCF7 EV NW\0box3TnWwY4Tpc44hSXO|YYm= M{e5OVExNTFyMDFOwG0> NXn3cpFHOuLCiXi= NUfhS4FRTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NX7ofnEzOjVyOEiyNFM>
MCF7 BMI1 NVj1b4czTnWwY4Tpc44hSXO|YYm= M{HtW|ExNTFyMDFOwG0> M3XGfVLjiImq NYjpUYF3TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NX:4UXY5OjVyOEiyNFM>
HepG2 NFzPV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQSG1UV8Li Mm\vTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= Mkn5NlUxPzh|MUG=
MOLT-3 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTqRpJFVVORwrC= MYPJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= NVvXcmt4OjVyN{izNVE>
HT1080 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnHN4p4OS1zMECg{txO NXnRZmJGPC9{ND:0PEBp M3W5bWROW00EoB?= MU\pcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NVPPTlhLOjVyN{iwOlQ>
HT1080 NIWzNHhHfW6ldHnvckBCe3OjeR?= NUG3OFF{OC5yMECxMVExOCEQvF2= M2PQT|EuOjRiaB?= MX7EUXNQyqB? M3rJXolv\HWlZYOgdE1xPTNqc3XyNVUqKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NWq2eolzOjVyN{iwOlQ>
HT1080 NV7x[ZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LNTFAvODByMT2xNFAh|ryP NEjDOmgzPCCq MmrpSG1UV8Li MUTjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| MVmyOVA4QDB4NB?=
HD-MY-Z MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7KenF1OjRxNEivO|IhcA>? NITwOGNKSzVy78{eNVAxKM7:TR?= NVHhe2VUOjVyNEiyN|Y>
DOHH-2 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCyOEBp MmPXTWM2OO,:nkGwNEDPxE1? NYC5NZRqOjVyNEiyN|Y>
DOHH-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj6R5dSPDhiaB?= NUTGSYFLUUN3ME2xPU46yqEQvF2= MYGyOVA1QDJ|Nh?=
DOHH-2 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXq3NkBp MlG4TWM2OD13wrFOwG0> NUflNYNFOjVyNEiyN|Y>
REH NEDDfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTyNlQhcA>? M3H4e2lEPTB;MD6wNlfDqM7:TR?= NHe5OHUzPTB2OEKzOi=>
REH MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK0PEBp MlizTWM2OD1yLkCxOOKh|ryP M1uwb|I2ODR6MkO2
REH MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXO|IhcA>? NXfqSVlKUUN3ME2wMlAyPcLizszN NUXmS3ZuOjVyNEiyN|Y>
HH NX\IWWZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2yOEBp MXLJR|UxRTFyND63xsDPxE1? NHTwTVEzPTB2OEKzOi=>
HH NITSfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG0PEBp NIfIVVBKSzVyPUS4MlbDqM7:TR?= MV6yOVA1QDJ|Nh?=
HH MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfVXFhPPzJiaB?= M2W1ZWlEPTB;MUSuO:Kh|ryP M2rSfVI2ODR6MkO2
HuT-78 NXnYUW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYeyOEBp NH3VSJhKSzVyPUmuN:Kh|ryP NVu1U3FsOjVyNEiyN|Y>
HuT-78 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT2foI1QCCq MXzJR|UxRTRwM9Mg{txO MlfZNlUxPDh{M{[=
HuT-78 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zhOVczKGh? NIrSWW1KSzVyPUSuNuKh|ryP M1PrflI2ODR6MkO2
OPM-2 M4HLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ZXJgzPCCq MUHJR|UxRTJ2LkJCpO69VQ>? NIr3b5YzPTB2OEKzOi=>
OPM-2 NXnSSm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG0PEBp Mn;uTWM2OD12wrFOwG0> MnjPNlUxPDh{M{[=
OPM-2 M2G0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWRVczKGh? MW\JR|UxRTFwM9Mg{txO Mle2NlUxPDh{M{[=
RPMI-8226 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm4N5gzPCCq M3fybWlEPTB;MUC2MlbDqM7:TR?= NUfQVmNjOjVyNEiyN|Y>
RPMI-8226 NFjrbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET4bWo1QCCq MUnJR|UxRTlzLkJCpO69VQ>? NWnlU48xOjVyNEiyN|Y>
RPMI-8226 NETQNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFriWFM4OiCq NYe5UIlJUUN3ME2xOE46yqEQvF2= MWiyOVA1QDJ|Nh?=
U-266 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3jNlQhcA>? M3PjcmlEPTB;OE[uNuKh|ryP NG\HZWkzPTB2OEKzOi=>
U-266 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILnZnQ1QCCq NGPu[2VKSzVyPU[4MlTDqM7:TR?= NXfMVlR6OjVyNEiyN|Y>
U-266 M13BVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPHPGQ4OiCq MUTJR|UxRTJ5LkVCpO69VQ>? NWqzcGlQOjVyNEiyN|Y>
Kelly MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LodVAuOTBizszN NYntSWgxPzMEoHi= MmHQTWM2OD1zLkWxPOKh|ryP MXqyOVAxQDlyMB?=
SH-SY5Y  NVXPWVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP3elcxNTFyIN88US=> M2DtVVczyqCq MlLuTWM2OD1yLke1OOKh|ryPwrC= M13HeVI2ODB6OUCw
SK-N-AS Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13GUVAuOTBizszN MWO3NuKhcA>? M3Lh[WlEPTB;MT63NVLDqM7:TdMg M3LY[VI2ODB6OUCw
SK-N-DZ M3rjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2zNE0yOCEQvF2= MofIO|LDqGh? M1vVS2lEPTB;NT60PFXDqM7:TR?= MXmyOVAxQDlyMB?=
HepG2 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60POKhcA>? M{nSVWROW00EoB?= NVPqUYN2UUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> NFLHW2EzPDl7NkGzOi=>
A549 NYT5ZpB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe0POKhcA>? NIOwdXlFVVORwrC= MorITWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= M{ezPFI1QTl4MUO2
MCF7 NHvPUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;NZlU1QMLiaB?= MmS2SG1UV8Li MnHRTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= Mn;tNlQ6QTZzM{[=
HL-60  M2nldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;0SZA4OsLiaB?= MXrJR|UxRTBwMUNihKXPxE1? M1jYOVI1QTl|MEG0
HL-60[R] NF63d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NuKhcA>? NWfIXlR[UUN3ME2zMlEz6oDHzszN NEHBPWszPDl7M{CxOC=>
MIAPACA NGTJZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHn[ZdIUTVyPUGuN{DDuSByLkCzJO69VQ>? MWmyOFk2Ozh{MR?=
MCF-7 NHri[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCfmdKPTB;MD6yOUDDuSByLkGg{txO M1jsZVI1QTV|OEKx
HeLa NWjRT2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfHTVUxRTBwNkSgxtEhOC52IN88US=> MnT3NlQ6PTN6MkG=
MO59K  NVnTRVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzIco44KGR? MX;JR|UxRTBwMUhihKXPxE1? MY[yOFk2OzV4MR?=
MO59J NF;r[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH4OlhMPyCm MkfOTWM2OD1yLkJihKXPxE1? M2Xt[VI1QTV|NU[x
ME 180 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1O2dLPDkEoHlCpC=> NWPVU5YzUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= MUiyOFk2OzB{Nx?=
MCF-7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr3Nlh6PDkEoHlCpC=> MXrJR|UxRTJ|LkmgxtEhOC5|4pEF{txO MVSyOFk2OzB{Nx?=
HeLa MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW0POKhcMLi M3fxUmlEPTB;ND63NUDDuSBzLkVihKXPxE1? MXiyOFk2OzB{Nx?=
MDA-MB-453 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITHNY01QMLiaNMg NH\T[mVKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= M{HI[VI1QTV|MEK3
MDA-MB-231 M2TuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHYOFjDqGkEoB?= NIrJNWpKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= NWLIS4psOjR7NUOwNlc>
PC-3 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OyNVQ5yqCqwrC= M2TqRWlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP MoSyNlQ6PTNyMke=
HT-29 M2DpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL5T3lQPDkEoHlCpC=> MlvHTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP NFjNPYwzPDl3M{CyOy=>
BGC-823 NV7OTGJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK0POKhcMLi M1zWZ2lEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= NFPpfXYzPDd7M{i3Oy=>
HeLa M2nvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4O5V1PDkEoHlCpC=> NVnUe5d{UUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO MX[yOFc6Ozh5Nx?=
A549 NX3mZWVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2d|Q5yqCqwrC= MYPJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP NUDRZnZWOjR5OUO4O|c>
HK-2 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[5PIg1QMLiaNMg MnTsTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NVKxZ3E1OjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID